BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nishioka T, Kubo S, Tanaka S, Wakasa K, Takemura S, Kinoshita M, Hamano G, Kuwae Y, Shibata T, Suehiro S. Outcomes of Hepatic Resection in Intrahepatic Cholangiocarcinoma Patients with Diabetes, Hypertension, and Dyslipidemia: Significance of Routine Follow-Up. Liver Cancer 2016;5:107-20. [PMID: 27386429 DOI: 10.1159/000367752] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 Hobeika C, Cauchy F, Poté N, Rautou PE, Durand F, Farges O, Dokmak S, Vilgrain V, Ronot M, Paradis V, Soubrane O. Short- and Long-Term Outcomes of Liver Resection for Intrahepatic Cholangiocarcinoma Associated with the Metabolic Syndrome. World J Surg 2019;43:2048-60. [PMID: 30949764 DOI: 10.1007/s00268-019-04996-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
2 Fu K, Yang X, Wu H, Gong J, Li X. Diabetes and PKM2 affect prognosis in patients with intrahepatic cholangiocarcinoma. Oncol Lett 2020;20:265. [PMID: 32989399 DOI: 10.3892/ol.2020.12128] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Murtha-Lemekhova A, Fuchs J, Feiler S, Schulz E, Teroerde M, Kalkum E, Klotz R, Billeter A, Probst P, Hoffmann K. Is metabolic syndrome a risk factor in hepatectomy? A meta-analysis with subgroup analysis for histologically confirmed hepatic manifestations. BMC Med 2022;20:47. [PMID: 35101037 DOI: 10.1186/s12916-022-02239-x] [Reference Citation Analysis]
4 Watanabe Y, Osaki A, Kimura K, Yakubo S, Takaku K, Sato M, Hashidate H, Waguri N, Terai S. Unresectable primary hepatic adenosquamous carcinoma successfully treated with systemic and transcatheter hepatic arterial injection chemotherapies followed by conversion surgery: a case report and literature review. BMC Gastroenterol 2021;21. [DOI: 10.1186/s12876-021-02070-3] [Reference Citation Analysis]